Residual Inflammation in Patients with Psoriasis Treated with Biologic Therapy: Findings from 3 Prospective Observational Cohorts
Clinical Summary
View sourceWhat was studied
Prospective observational analysis across 3 cohorts (Spain, United States, Sweden) of 209 psoriasis patients on stable biologic therapy who achieved PASI ≤ 2, assessing residual inflammation defined as hs-CRP ≥ 2 mg/L.
Key findings
Residual inflammation was present in 36.3% of patients and was associated with higher BMI, metabolic dysfunction–associated steatotic liver disease, greater baseline systemic inflammation, and visceral adipose tissue; female sex predicted residual inflammation in all 3 cohorts.
Clinical implications
Even when skin disease is controlled on biologics (PASI ≤ 2), about one-third of psoriasis patients show systemic inflammation (hs-CRP ≥ 2 mg/L); screen and address obesity and fatty liver disease as modifiable drivers.
Related Questions
Explore related topics and deepen your understanding